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Objectives: Early in the COVID-19 pandemic, people with underlying comorbidities
were overrepresented in hospitalised cases of COVID-19, but the relationship between
comorbidity and COVID-19 outcomes was complicated by potential confounding by age.
This review therefore sought to characterise the international evidence base available
in the early stages of the pandemic on the association between comorbidities and
progression to severe disease, critical care, or death, after accounting for age, among
hospitalised patients with COVID-19.
Methods: We conducted a rapid, comprehensive review of the literature (to 14
May 2020), to assess the international evidence on the age-adjusted association
between comorbidities and severe COVID-19 progression or death, among hospitalised
COVID-19 patients – the only population for whom studies were available at that time.
Results: After screening 1,100 studies, we identified 14 eligible for inclusion. Overall,
evidence for obesity and cancer increasing risk of severe disease or death was most
consistent. Most studies found that having at least one of obesity, diabetes mellitus,
hypertension, heart disease, cancer, or chronic lung disease was significantly associated
with worse outcomes following hospitalisation. Associations were more consistent for
mortality than other outcomes. Increasing numbers of comorbidities and obesity both
showed a dose-response relationship. Quality and reporting were suboptimal in these
rapidly conducted studies, and there was a clear need for additional studies using
population-based samples.
Conclusions: This review summarises the most robust evidence on this topic that was
available in the first few months of the pandemic. It was clear at this early stage that
COVID-19 would go on to exacerbate existing health inequalities unless actions were
taken to reduce pre-existing vulnerabilities and target control measures to protect groups
with chronic health conditions.
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INTRODUCTION
After first emerging at the end of 2019, the novel coronavirus
SARS-CoV-2 had infected at least 4.6 million people globally by
mid-May 2020, with 0.3 million deaths. By July 2021, this had
increased to at least 178.8 million people infected and 3.8 million
deaths (1). The pandemic remains uncontained in many parts
of the world, raising grave concerns about vaccine distribution
keeping pace with subsequent waves and new variants. To
minimise mortality and morbidity as the pandemic continues,
and to direct scarce resources most appropriately, it is crucial
to understand better the risk factors for progression to severe
coronavirus disease 2019 (COVID-19) and death. It is also
important to capture the nature of the evidence that was available
to policymakers in the early months of the pandemic, especially
given the many government enquiries that will be undertaken
around the world into how well the early response tackled
the crisis.
Initial reports from China and Italy suggested that people
with underlying comorbidities were overrepresented in
hospitalised cases and were at increased risk of progression to
severe disease and death (2–4). Other countries subsequently
reported similar findings (5, 6). Given that the prevalence of
comorbidity increases with age, it was unclear whether and how
comorbidity independently influences COVID-19 outcomes.
Many early studies of COVID-19 epidemiology reported
baseline comorbidities of hospitalised patients but not age-
adjusted estimates of excess risk associated with comorbidities.
Given the high prevalence of chronic disease globally (7), a
better understanding of the age-adjusted relationship between
comorbidity and COVID-19 outcomes would enhance health
service planning and inform clinical management.
We conducted a rapid but comprehensive review of studies in
the early stages of the pandemic when hospitalised patients were
the population subgroup most readily accessible for research.
We are mindful, however, of potential selection bias in these
samples due to differential healthcare use, limited SARS-CoV-
2 testing in the wider population, and under-ascertainment of
asymptomatic and mild cases (8). This review therefore sought to
characterise the international evidence base available in the early
stages of the pandemic on the association between comorbidities
and progression to severe disease, critical care, or death, after
accounting for age, among hospitalised patients with COVID-19.
We considered evidence to mid-May 2020, 5 months after the
viral infection was first identified in Wuhan, China, and only 2
months after the World Health Organization (WHO) declared it
a pandemic.
METHODS
Search Strategy and Selection Criteria
Our search was designed to address the question: according
to the evidence base in the early stages of the COVID-19
pandemic, what was the age-adjusted association between co-
morbidities and severe outcomes in hospital patients? We
searched the literature to identify age-adjusted estimates of
association between any comorbidity and in-hospital severe
COVID-19 outcomes (Table 1), reported in peer-reviewed
studies, pre-prints from repositories such as medRxiv, and
several grey literature sources, published by 14 May 2020, in
English, from any country (some searches preceded this date;
see below). We defined comorbidity as a pre-existing health
condition present at admission to hospital with COVID-19,
including obesity but excluding health-related behaviours such
as smoking.
The search strategy had five arms (Figure 1). First (7
April; updated 12 May 2020), we searched the MEDLINE
full-text database (as title and abstract often omit age-
adjustment) to identify analytical (rather than descriptive)
studies that focused on comorbidities specifically or that
reported multivariable analysis of risk factors (including
comorbidities) for severe outcomes of COVID-19 (see Appendix
1 in Supplementary Material for full search terms). Second
(on 14 May), we searched the medRxiv pre-print database.
Third, we screened studies from our companion review
on COVID-19 critical care outcomes (Pennington et al.
unpublished, which by then had screened 2,665 items) for
any meeting our narrower search criteria. Fourth, all studies
identified in that companion review underwent Web of
Science and Google Scholar forward-citation searches, with
initial filtering for key terms relating to comorbidity and
age (on 7 April). Fifth, additional sources searched (initially
in April; updated 11 May) included: WHO; communicable
disease centres of the USA, Europe, and China; and several
COVID-19-specific evidence resources online (“other sources”
in Figure 1; see Appendix 1 in Supplementary Material
for details).
Screening for Inclusion
In Arms 1 and 2, title-abstract screening by one reviewer
excluded studies clearly not meeting the inclusion criteria,
followed by independent title-abstract screening of the remainder
by two reviewers in EPPI Reviewer-4 (11). In each of Arms
3–5, title-abstract screening was followed by full-text screening
by a single reviewer. Outputs of Arms 1–5 were combined,
and remaining duplicates were excluded. To facilitate this
rapid review, three reviewers shared searching and screening
tasks, rather than repeating tasks independently, except where
otherwise stated. Two reviewers independently screened the full
text of the final set of potentially eligible studies. On 27 May,
included pre-prints were checked for subsequent peer-reviewed
publication (and again a year later for the post-script of this
definitive article).
Data Extraction
One reviewer extracted age-adjusted estimates of excess risk
(odds ratios or hazard ratios) associated with any comorbidity
for the outcomes of interest. A second reviewer checked
each extraction for accuracy. Where studies reported multiple
estimates adjusted for different sets of covariates (e.g., age
alone, age plus sex), one reviewer extracted all estimates then,
with checking by others, selected the most appropriate estimate
for reporting in the review, prioritising the most appropriate
Frontiers in Public Health | www.frontiersin.org 2 August 2021 | Volume 9 | Article 584182
Mason et al. Comorbidity and COVID-19 Outcomes Review
TABLE 1 | Review inclusion and exclusion criteria: what was the age-adjusted association between comorbidities and severe or critical care outcomes in hospital patients
with COVID-19 in the early stages of the pandemic?
Include Exclude
Population Adult COVID-19 hospital patients.
Studies with 10 or more patients.
Samples nested in clinical trials, samples from cruise ships, familial clusters.
Community cases not receiving care in hospitals, including general population
estimates of the spread of COVID-19.
Studies focusing solely on infants and children (not part of a study including adults).
Outcomes Relative risk, hazard ratio, odds ratio associated with
comorbidity (pre-existing condition, chronic illness)
status on admission, of:
i. progression to severe disease
ii. admission to critical or intensive care unit
iii. invasive or non-invasive ventilation
iv. death in hospital
v. any adverse event (i.e., composite indicators of any
of i–iv),
for any reported comorbidity.
Other treatments inside and outside critical or intensive care departments, e.g., rates
of patients receiving oxygen supplementation.
Comparison Patients with and without any comorbidity at admission
to hospital. Comorbidity was defined as pre-existing
health conditions present at admission to hospital with
COVID-19, including obesity.
Comparisons within a sample of patients who all have a comorbidity (e.g., studies of
cancer patients only). Comparisons between groups of people based on their
health-related behaviours (e.g., smoking), ethnicity, or socioeconomic circumstances.
Study design All primary quantitative empirical observational studies
that reported estimates of the independent relative
hazard/odds of experiencing a severe outcome
according to comorbidity status, adjusted for age only, or
age and other plausible confounders of that association.
Any studies in which all estimates of excess risk associated with comorbidity were
also adjusted for potential mediators between comorbidity and severe disease
outcomes, such as clinically ascertained biomarkers (e.g., inflammatory response or
organ function). Causal interpretation of hazard/odds ratios is inappropriate from
models not designed to account for confounding of the exposure-outcome
association of interest (9, 10), therefore in this review estimates would likely be biased
towards the null if adjusted for clinical biomarkers.
Qualitative studies.
Intervention studies (e.g., clinical trials of new treatments for COVID-19).
Projections or estimations of potential outcomes.
Non-empirical studies, including editorials, opinions, or discussion pieces.




Publication stage, type Pre-prints, peer-reviewed publications, grey literature on
empirical evidence (e.g., official statistics).
Not applicable.
Language English language publications. Non-English language publications (not available for full text).
Date Studies published between December 2019 and 14th
May 2020.
adjustment, e.g., for age and sex rather than age alone and not
including potential mediators.
Synthesis
Evidence was synthesised narratively (12, 13) and, after piloting,
study quality was assessed using a modified version of the
Institute of Health Economics (14) quality appraisal checklist for
case series studies (as recommended by the National Institute
of Health and Care Excellence). Limited numbers of studies
assessing each individual comorbidity, heterogeneity in key
measures and statistical methods, and the inclusion of non-peer-
reviewed pre-prints meant that meta-analysis was inappropriate.
Extracted estimates are summarised in forest plots. Studies of
mortality reported a mix of hazard ratios (HRs) and odds ratios
(ORs), so we present both in the forest plots, but it should be
noted that ORs and HRs are not directly comparable – ORs
overestimate the relative risk of an outcome in studies (such as
these) where the outcome is common (15).
RESULTS
Overall, 1,100 titles-abstracts and 118 full texts were screened
(see Figure 1 for exclusions). Of those 118 full texts, 101 were
identified in the MEDLINE search, nine from medRxiv, three
from the forward citation search from the companion review,
and five from other sources. After full-text screening, 14 studies
(16–29) met the inclusion criteria. Of these, seven were published
in peer-reviewed journals and seven were identified in non-peer-
reviewed pre-print form. Four of the pre-prints were included in
the review as pre-prints (19, 25, 26, 29) while three were replaced
with a peer-reviewed version before analysis (16, 18, 24).
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FIGURE 1 | Flowchart of progression of studies through the review of age-adjusted associations between comorbidity and outcomes of COVID-19 in the early stages
of the pandemic.
Characteristics of the Included Studies
Six of the included studies were from China during the initial
stages of the pandemic. Three of these used data from Wuhan
and the Hubei province, the epicentre of the Chinese outbreak
(17, 27, 29), while the others focused on cases hospitalised outside
Hubei, using either national samples (20), city-wide reporting
systems (28), or records from a single tertiary hospital in another
province (16). Four studies used data from the USA (19, 21, 22,
24), three from the UK (18, 25, 26), and one from Iran (23).
Eight were multi-centre studies. Sample sizes for the relevant
estimates ranged from 103 (21) to 15,194 (18). Study quality
varied from low (quality score 8/20) to moderately high (15/20)
(Table 2; Supplementary Figure 1). The narrative synthesis of
results focuses more on larger and higher quality studies.
Included studies mostly reported retrospective analyses of
hospital records, usually with a case series or retrospective
cohort study design and assessing associations between multiple
risk factors, including comorbidities, and various outcomes.
Although many were labelled as cohort studies, they did not
generally recruit a random sample (convenience sampling was
common), and many did not clarify whether the duration of
follow-up allowed all participants to reach a study endpoint or
recover. Detail of sample construction in many studies was scant.
For the outcome, three studies reported a composite severe
endpoint (all including death or admission to ICU) (17, 20, 26),
seven reported death (18, 22–25, 27, 29), and four reported
severe disease, including ICU admission (16, 19, 21, 28). Three
examined mechanical ventilation or intubation as a separate
endpoint (19, 21, 24).
Comorbidities analysed by more than one study were
overweight and obesity (five studies), diabetes mellitus (seven
studies), hypertension and heart disease (seven studies), cancer
(four studies), and chronic respiratory conditions such as
chronic obstructive pulmonary disease (COPD) (five studies).
The largest study also examined dementia, kidney disease, liver
disease, and neurological conditions (not defined but giving
stroke as an example). Additionally, four studies reported
the association of one of the outcomes with the presence
of any (or multiple) comorbid conditions rather than, or as
well as, specific conditions (19, 20, 23, 25). Eight studies
collated information on comorbidities from medical records,
two studies included self-reported comorbidities, and four did
not report the data collection method. Two studies reported
robust methods of collating data on comorbidities involving
cross-checking primary and secondary care records (25) or
quality checks on extracted data (19). Only two studies mapped
comorbidities to International Classification of Disease (ICD)-10
codes (19, 25).
All studies adjusted for age using multivariable regression
models [Cox proportional hazards (n = 5), logistic (n = 8),
both (n = 1)]. All but two studies also adjusted for one or
more additional covariates, but these differed across studies.
Additional covariates used in more than one study included
sex, smoking, other specific comorbidities, and ethnicity.
Although several papers acknowledged that missingness
would probably be substantial in a pandemic context,
only four formally reported missing data, and two imputed
missing values.
Frontiers in Public Health | www.frontiersin.org 4 August 2021 | Volume 9 | Article 584182
Mason et al. Comorbidity and COVID-19 Outcomes Review
TABLE 2 | Summary of included studies in review of age-adjusted associations between comorbidity and outcomes of COVID-19 in the early stages of the pandemic.
References Comorbidities analysed Setting Single- or multi-
centre study
Sample size Quality score
(max. 20)
Sapey et al. (25) Any (of hypertension, diabetes mellitus, cancer,
chronic lung disease, and others)
Birmingham, UK Multi 2,217 15
Docherty et al. (18) Obesity, hypertension, heart disease, diabetes,
cancer, chronic lung disease (non-asthma), and
others
UK (nationwide) Multi 15,194 14
Cai et al. (16) Obesity Shenzhen, Guangdong
Province, China
Single 387 14
Wang et al. (27) Hypertension, heart disease Wuhan, Hubei Province,
China
Single 296 14
Palaiodimos et al. (24) Obesity New York, USA Single 200 14
Guan et al. (20) Hypertension, diabetes, cancer, chronic
obstructive pulmonary disease; and any in
combination
China (nationwide) Multi 1,590 13
Zhang et al. (29) Diabetes mellitus Wuhan, Hubei Province,
China
Single 258 13
Kalligeros et al. (21) Obesity, hypertension, heart disease, diabetes,
lung disease
Rhode Island, USA Multi 103 13
Teo et al. (26) Hypertension, ischaemic heart disease,
diabetes mellitus
London, UK Multi 437 12
Ebinger et al. (19) Obesity, hypertension, heart disease, diabetes
mellitus, chronic obstructive pulmonary disease
or asthma; and any in combination
Los Angeles, USA Multi 214 12






Any (of hypertension, cardiovascular disease,
diabetes, cancer, chronic lung disease, and
other)
Tehran, Iran Single 2,964 10




Yu et al. (28) Hypertension, heart disease, diabetes, lung
disease
Shanghai, China Multi 333 8
Comorbidity and Severe COVID-19
Outcomes: Disease Progression, Critical
Care, and Mortality
Across all comorbidities, the studies with the largest sample
sizes and widest geographical coverage consistently showed
evidence of increased risk of severe COVID-19 outcomes
following hospitalisation associated with the presence of the
comorbidity. These associations appeared to hold over studies
of varying quality. Smaller studies tended to report similar point
estimates to the larger studies but with wide confidence intervals,
sometimes consistent with no association, possibly indicating
insufficient statistical power. Evidence was most consistent for
associations between comorbidities and death but more mixed
for other outcomes (Figures 2–5; Supplementary Table 1).
Any Comorbidity and Multiple Comorbidities
Hospitalised patients with any comorbidity were more likely
to be admitted to ICU, require invasive ventilation, or die
from COVID-19, in three of the four studies that examined
comorbidities collectively. In a study of 2,217 patients in a large
UK city, Sapey et al. examined the effect of “any comorbidity” on
mortality and found evidence of a dose response after adjusting
for age, sex, ethnicity, and deprivation (25). Patients with one
or two comorbidities had a 115% greater hazard of death than
patients without comorbidities (95% CI: 1.50, 3.09), and those
with three or more had 200% increased hazard of death (95%
CI: 2.09, 4.31). Similarly, in a nationwide study of 1,590 patients,
Guan et al. (20) also found a dose-response relationship: after
adjustment for age and smoking status, patients with a single
comorbidity had a 79% greater hazard of a severe outcome
than patients without comorbidities, while those with multiple
comorbidities had a 159% increased hazard (HR= 2.59, 95% CI:
1.61, 4.17). A study of mortality in 2,964 patients in Iran reported
an odds ratio of 1.53 (95% CI: 1.04, 2.24) for any comorbidity
compared with none (23). In contrast, a small study in the USA
(19) reported on a validated comorbidity score and found no
significant association between a standard deviation increase in
the comorbidity score and either ICU admission (OR= 1.12, 95%
CI: 0.86, 1.47) or intubation (OR= 0.86, 95% CI: 0.63, 1.18).
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FIGURE 2 | Forest plot of study estimates of the association between comorbidities and COVID-19 mortality among hospitalized patients. Reference category for
each comorbidity is the absence of that comorbidity, except where stated otherwise. HR, hazard ratio (red); OR, odds ratio (blue); CI, confidence interval; BMI, body
mass index; COPD, chronic obstructive pulmonary disease. All estimates adjusted for age. Additionally adjusted for: sex [s]; other comorbidities [c]; ethnicity [e];
deprivation [d]. *95% CI not reported, but back-calculated from reported p-value.
Overweight and Obesity
In the largest study, Docherty et al. (18) reported hazard ratios
for various comorbidities and other risk factors among 15,194
COVID-19 patients in UK hospitals. They found that obesity
was associated with higher risk of COVID-19 mortality, after
adjusting for age, sex, and other comorbidities (HR = 1.33,
95% CI: 1.19, 1.49). In two US studies, severe obesity (BMI
≥35 kg/m2) was associated with higher odds of requiring
invasive ventilation or dying from COVID-19 (24) compared
with people who were overweight or moderately obese, and
with higher odds of progressing to severe COVID-19 (21)
compared with people of normal weight, independent of age,
sex, and ethnicity. Cai et al. (25) examined the relationship
between overweight and obesity and progression to severe
pneumonia in 387 hospitalised COVID-19 cases in Shenzhen,
a Chinese city in Guangdong province. They found that
obesity significantly increased the age-adjusted risk of COVID-
19 patients developing severe pneumonia (OR = 3.35, 95% CI:
1.47, 7.63). A dose-response relationship was observed, with
overweight patients at intermediate risk relative to patients of
healthy weight (OR= 1.78, 95% CI: 1.00, 3.21). This relationship
was particularly pronounced in men (OR = 5.40, 95% CI 1.93,
15.09). In contrast, a study of 214 COVID-19 patients in Los
Angeles, USA, found no evidence of an association between
either overweight or obesity and severe disease, or the need for
invasive ventilation, having adjusted for age and sex (19).
Hypertension and Heart Disease
Evidence of a relationship between pre-existing hypertension or
heart disease and severe COVID-19 outcomes was mixed. In
China, Guan et al. found that, after adjusting for age and smoking
status, patients with hypertension at admission were 58% more
likely to reach the composite severe endpoint (ICU admission,
invasive ventilation, or death) than those without hypertension
(HR = 1.58, 95% CI: 1.07, 2.32) (15). All other studies that
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FIGURE 3 | Forest plot of study estimates of the association between comorbidities and composite severe endpoint (death, intensive care unit admission, severe or
critical symptoms, or invasive mechanical ventilation) among hospitalized COVID-19 patients in the early stages of the pandemic. Reference category for each
comorbidity is the absence of that comorbidity, except where stated otherwise. ICU, intensive care unit; HR, hazard ratio; OR, odds ratio; CI, confidence interval;
COPD, chronic obstructive pulmonary disease. All estimates adjusted for age. Additionally adjusted for: smoking [sm]; sex [s]; other comorbidities [c]; ethnicity [e].
examined hypertension (in the UK, China, and the USA) found
no evidence of an association with any outcome (19, 21, 26–28).
For chronic heart disease, Docherty et al. (18) found pre-
existing disease was associated with higher risk of mortality after
adjusting for age, sex, and other comorbidities (HR = 1.16, 95%
CI: 1.08, 1.24). Evidence from other studies was mixed. Kalligeros
et al. for example, found heart disease to be associated with
greater odds of the need for invasive ventilation but not with
admission to intensive care (21).
Diabetes Mellitus
In studies examining diabetes mellitus as a comorbidity, authors
did not distinguish between Type 1 and Type 2 diabetes. The
large UK study of 15,194 patients reported a small (6%) but non-
significant increased hazard of death for people with compared
with those without diabetes following hospitalisation with
COVID-19 after adjusting for age, sex, and other comorbidities
(HR = 1.06, 95% CI: 0.99, 1.14) (18). The nationwide study
in China (20) found that hospitalised COVID-19 patients with
diabetes had a 59% increased risk of the composite severe
endpoint (ICU admission, invasive ventilation, or death) (HR
= 1.59, 95% CI: 1.03, 2.45), independent of age and smoking
status. Similarly, in a study of 258 COVID-19 patients at a
Wuhan hospital, those patients with diabetes were more likely
to die in hospital HR = 2.84, 95% CI: 1.01, 8.01) (29). In
contrast though, four other studies found no evidence of an age-
adjusted association between diabetes and any severe outcome
(19, 21, 26, 28).
Cancer
All four studies examining cancer found it to be a risk factor
for severe outcomes following hospitalisation with COVID-19.
Docherty et al. (18) found a slightly elevated risk of death
amongst UK-based COVID-19 patients with cancer (HR = 1.13,
95% CI: 1.02, 1.24). Guan et al. (20) found a substantially elevated
risk of their composite severe endpoints – after adjusting for age
and smoking status, patients with cancer had 3.5-fold the hazard
of ICU admission, invasive ventilation, or death in hospital
compared with patients without cancer (95% CI: 1.60, 7.64). Dai
et al. (17) found a similar relationship in their sample of cancer
patients and matched non-cancer patients in Hubei province,
China (HR= 2.52, 95%CI: 1.66, 3.83) after additionally adjusting
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FIGURE 4 | Forest plot of study estimates of the association between comorbidities and progression to severe disease or intensive care unit admission among
hospitalized COVID-19 patients in the early stages of the pandemic. Reference category for each comorbidity is the absence of that comorbidity, except where stated
otherwise. ICU, intensive care unit; OR, odds ratio; CI, confidence interval; BMI, body mass index; COPD, chronic obstructive pulmonary disease; MI, myocardial
infarction. All estimates adjusted for age. Additionally adjusted for: sex [s]; other comorbidities [c]; ethnicity [e].
for other comorbidities. They also reported relative hazards by
cancer stage and type, finding that association with the composite
severe endpoint was strongest for metastatic cancer and for lung
and blood malignancies. Mehta et al. (22) used a similar study
design and reported an age- and sex-adjusted odds ratio of 2.45
for cancer and in-hospital mortality.
Chronic Obstructive Pulmonary Disease
Five studies reported associations with pre-existing lung disease,
either COPD specifically (20) or a broader set of pulmonary
conditions (18, 21, 25, 28). One study excluded asthma, two
included asthma, and one study did not state whether asthma
was included. Docherty et al. reported 17% increased hospital
mortality associated with non-asthmatic pulmonary disease (HR
= 1.17, 95% CI: 1.09, 1.27), independent of age, sex, and other
comorbidities (18). Guan et al. found that hospitalised patients
with COPD had 168% higher risk of reaching that study’s
composite severe endpoint (ICU admission, invasive ventilation,
or death) than patients without COPD (HR = 2.68, 95% CI:
1.42, 5.05), adjusted for age and smoking status (20). None of
the three remaining studies – using endpoints of progression to
severe disease and invasive ventilation – found an association
with chronic lung disease, broadly defined (19, 21, 28).
Other Comorbidities
One large UK-wide study also found neurological disorders
(giving the example of stroke), dementia, liver disease, and
chronic kidney disease were all associated with increased
risk of mortality after adjusting for age, sex, and other
comorbidities (18).
Post-script: Of the four pre-prints included in the analysis
(19, 25, 26, 29), a final check in May 2021 found that two
(19, 25) now had a peer-reviewed publication (30, 31). There were
no substantive changes in reported evidence in the published
versions compared with the pre-print versions.
DISCUSSION
Summary of Findings
Five months after the first outbreak of COVID-19 in Wuhan,
China, and 2 months after the WHO declared COVID-
19 a pandemic, research was limited on comorbidities as
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FIGURE 5 | Forest plot of study estimates of the association between comorbidities and invasive mechanical ventilation among hospitalized COVID-19 patients in the
early stages of the pandemic. Reference category for each comorbidity is the absence of that comorbidity, except where stated otherwise. OR, odds ratio; CI,
confidence interval; BMI, body mass index; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease. All estimates adjusted for age. Additionally
adjusted for: sex [s]; other comorbidities [c]; ethnicity [e].
independent risk factors for severe COVID-19. Our review of
that emerging evidence base indicates that by mid-May 2020
there was broad support (32) for the hypothesis that many
underlying health conditions confer additional risk of mortality
among people hospitalised with COVID-19, independent of
age. Evidence of increased risk of other severe COVID-19
outcomes was mixed. Most studies found that having at least
one of obesity, diabetes, hypertension, heart disease, cancer,
or COPD was significantly associated with worse outcomes
following hospitalisation. A dose-response relationship was
reported for increasing numbers of comorbidities, and evidence
linking overweight and obesity to severe outcomes was strongest
for more severe obesity. Overall, evidence for obesity and
cancer increasing risk of severe disease or death was most
consistent, with all but one of the numerous relevant studies
reporting an increased risk associated with these conditions.
Evidence was weakest for hypertension as an independent risk
factor for severe outcomes. Two similar reviews that were
published whilst our rapid review was under peer review –
and included some more recent studies – found similar results
(33, 34), although another found no association with obesity in
meta-analysis (33–35).
Comorbidity has previously been shown to be associated with
elevated risk of worse clinical outcomes in other severe acute
respiratory outbreaks such as SARS (severe acute respiratory
syndrome), MERS (Middle East respiratory syndrome), and
avian influenza (36–38). This review suggests that comorbidity
also pre-disposes individuals to poorer outcomes in the
current COVID-19 pandemic. Whilst the mechanisms remain
poorly understood, there are numerous biologically plausible
explanations. The pathogenesis of severe COVID-19 is thought
to involve dysregulated proinflammatory immune response and
subsequent multi-system damage (39–41). Many underlying
conditions may leave affected individuals more vulnerable to
the effects of this. Obesity tends to reduce lung function and
dysregulate the immune system (42). Similarly, diabetes mellitus
can impair immune function (43), as do many cancer treatments.
Patients with pre-existing cardiovascular disease may be at
heightened risk of severe outcomes through various mechanisms,
including therapeutic upregulation of ACE2 (the host receptor
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for SARS-CoV-2) and greater vulnerability to hyperinflammatory
immune responses and cardiac complications that are common
with severe COVID-19 (9, 44).
Strengths and Limitations of the Evidence
Base
This review includes two studies that are still to undergo peer-
review. Such studies must be treated cautiously, but the need to
summarise timely evidence in an emerging pandemic justifies
including them, while requiring “a permanent critical attitude
from the readers” (45). Of the other two studies originally
included in pre-print form but subsequently peer-reviewed and
published within a year of the analysis, we noted no substantive
differences between the pre-print and published version. Quality
appraisal revealed important limitations in most included
studies: weaknesses in design or execution, inadequate detail, or
lack of clarity in reporting, particularly around sampling, and
inclusion and exclusion criteria.
Our review is limited to the hospitalised population of
COVID-19 cases, a highly selected sample of the population.
These studies are therefore at risk of selection (or collider) bias
(46), which can induce spurious associations leading to flawed
conclusions, particularly when the prevalence of a risk factor in
the sample differs from its prevalence in the target population
(8, 47). Viral load is an unmeasured factor that may differ
between hospitalised and non-hospitalised COVID-19 patients
and also be associated with risk of severe outcomes. In several
included studies, obesity prevalence differed considerably in the
study population from the wider population of the same country
(16, 18, 19). The extent of missing data was also underreported
in many studies, possibly adding further selection bias. The
results therefore may not reflect causal effects, and there remains
a need for confirmation with larger, population-based studies.
Although some studies in this review acknowledged possible
selection bias (and it was probably unavoidable early in an
outbreak context) none included sensitivity analyses to assess
this risk. Furthermore, patients in many studies had not yet
reached their clinical endpoint. We now also note that similar
reviews were published while ours was under peer review, and
are also primarily focused on samples of hospitalised patients
[e.g., (33–35)].
There was substantial heterogeneity in outcome and
comorbidity definitions and the clarity of their reporting,
compromising comparison of results and precluding pooling
of estimates. Most studies used electronic health records, but
many did not clearly specify data collection methods in any
further detail, particularly for recording comorbidities. In
some, lack of rigour in comorbidity ascertainment might have
led to misclassification, but without more information it is
difficult to assess how likely this is as a source of bias. Only two
studies included ICD-10 criteria for comorbidities, no study
distinguished between Type 1 and Type 2 diabetes, and BMI
categorisations also differed between studies.
Across studies, models differed considerably in adjusting
for obvious confounders, such as sex or smoking, making
comparison challenging. By excluding studies reporting models
that contain clinical predictors of disease progression, we
excluded hazard ratios or odds ratios for comorbidity that were
likely to overadjust for potential mediators (e.g., inflammation)
of the possible effect of comorbidity on progression to a
severe COVID-19 outcome. We did retain studies that adjusted
estimates for one comorbidity by other comorbidities, although
this may also lead to overadjustment if one comorbidity mediates
another’s effect on the outcome (e.g., Type 2 diabetes mediated
by obesity). Some of the included estimates are potentially
susceptible to residual confounding from omitted confounders
such as ethnicity and socioeconomic disadvantage. The estimates
in this review do tend, however, to be similar in magnitude across
adjustment for various confounders.
Overall, the 14 studies varied considerably in both the
quality of the design and reporting, and only a few were
moderately high quality. Whilst hasty research and publication
are understandable early in such a global emergency, rigour
should not be compromised. As London and Kimmelman
argued, “the moral mission of research remains the same: to
reduce uncertainty and enable caregivers, health systems, and
policy-makers to better address individual and public health”
(48). Indeed, there is an ethical imperative to ensure that the
conduct and reporting of research in a pandemic crisis maintains
high standards of validity, reliability, and integrity to provide
sufficiently robust evidence for these purposes.
Strengths and Limitations of the Review
Our review was rapid while also being as comprehensive as
possible for that period of the pandemic. A companion review
provided forward-citations, and our full-text searches included
both pre-print archives and peer-reviewed literature, reflecting
the fast-moving early stages of the pandemic and the increasing
use of pre-print archives. Full texts were independently screened
by two reviewers. To aid interpretation of the synthesised results,
we systematically assessed study quality after modifying an
existing tool to provide an appropriate appraisal framework for
these studies.
The timing of the review meant that almost half the included
studies came from China, and the others were restricted to a
few other settings. The Chinese studies may have had a healthier
case-mix because of different criteria for admission compared
with other countries (e.g., the United Kingdom), where only
relatively serious cases are hospitalised. The comorbidity profile
of China also differs from many other countries (49–51). Our
reliance on studies of hospitalised patients means the conclusions
only indicate the increased risk associated with comorbidities
in hospitalised COVID-19 patients rather than the effect that
comorbidities may have on the initial risk of being infected
with SARS-CoV-2 or on the outcomes of people with COVID19
outside hospital (e.g., in care homes). As noted above, selection
biasmay also affect these results. There is also a risk of publication
bias - given the short time period, at least some studies published
early in the pandemic are likely to have traded quality against the
need for timely information. This demonstrates the importance
of characterising the early evidence base, so it can later be
contrasted will the evidence gathered over the longer run of
the pandemic.
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The primary focus of this review was to improve
understanding of the independent relationships between
comorbidities and COVID-19 outcomes, hence we collated
evidence from studies where likely confounding by age had
been appropriately controlled. With the exception of one
meta-analysis that coarsely stratified by age (34), we note that
subsequent similar reviews, published while ours was under
peer review, have tended not to address explicitly the issue
of heterogeneity across studies in terms of whether potential
confounding by age was accounted for.
Implications for Future Data Collection and
Research
Early studies will have informed policy decisions in this fast-
moving pandemic. Speedy publication in a global emergency
necessitated “loosening the critical parameters” (45) for
the evidence base, and our quality appraisal suggests that
reporting of methods has been adversely affected. Nevertheless,
transparent and detailed reporting remains necessary for
accurate interpretation. A lesson for future pandemics would
be that having pre-agreed international guidelines on consistent
methods and reporting of sample selection, description, and
design (including variables to be measured and data collection
tools) would facilitate more effective use and application of
research efforts, by enabling pooling of results from different
locations and settings to provide high-quality evidence quickly.
Caniglia et al. (10) argued that science during a pandemic
must accommodate unavoidable uncertainty whilst maintaining
science’s social responsibility to the public good. This would
include ensuring better skills, capacity, and theoretical
frameworks are in place to enable better mobilisation of
evidence under conditions of high uncertainty. Early in the
pandemic, hospital-based studies were the most feasible, but
population-based studies must now play a larger role in clarifying
understanding of various independent risk factors for severe
outcomes fromCOVID-19. Several such studies started emerging
from May 2020 onwards [e.g., (52)], but making meaningful
inferences can still be challenging (53). Regardless of study
design, future studies should attempt to evaluate the robustness
of conclusions to plausible sources of selection and other biases.
Implications for Policy and Practice
As early as May 2020, it was apparent that various comorbidities
conferred an increased risk of severe disease progression and
death after being hospitalised with COVID-19, independent
of age. The evidence was slightly more consistent for obesity,
although many other common chronic conditions across
organ systems seemed to confer an elevated risk, and
there is evidence that multimorbidity adds further risk.
Given the relatively high population prevalence of most
comorbidities covered in this review, the implications of
elevated risk are substantial. It has been estimated from
Global Burden of Disease prevalence data that one in five
individuals globally may be at increased risk of severe
COVID-19 due to underlying conditions (54), but this is
likely to underestimate risk because obesity was omitted.
Furthermore, this burden is not evenly distributed between
countries, meaning COVID-19 is impacting healthcare
systems already under pressure from high local burdens of
non-communicable disease.
Whether COVID-19 accelerates the underlying condition,
or weakened underlying organs or immune response increase
vulnerability to severe COVID-19, or both, is subject to ongoing
research globally. Nevertheless, even without a full explication of
the mechanisms, early epidemiological evidence of an association
between comorbidities and poor in-hospital outcomes supported
action to protect these groups and mitigate their elevated risk.
The increased risk associated with many comorbidities
supported strong, targeted primary prevention measures
to “shield” people with comorbidities from SARS-CoV-
2 and suggested a need for public health campaigns to
promote awareness of these elevated risks and how people
could protect themselves. Vaccines have been prioritised for
those at higher risk. In terms of secondary prevention of
COVID-19, it is important to detect it early in those with
comorbidities, to reduce progression as treatments (such as
dexamethasone for severe or critical disease) emerge. This
evidence has implications for healthcare system demand
in areas of high comorbidity prevalence. To address the
greater burden of COVID-19 in communities with more
pre-existing conditions, greater resources should be allocated
according to this need. Approaches in the early stages of the
pandemic were, however, not prioritising sufficiently these
higher levels of need (55). There are also implications when
preparing for subsequent waves of community transmission.
In particular, the evidence presented here highlights greater
urgency for reducing the prevalence and incidence of chronic
disease, through support for non-communicable disease
prevention efforts and addressing the wider determinants
of health.
Finally, the intersection of underlying comorbidity with
socioeconomic disadvantage, geography, and demographic
factors, especially ethnicity, has proven to be a potent mix
that will widen health inequalities, both within and between
countries. In England, official statistics showed that COVID-
19 age-standardised mortality rates in the most deprived
parts of England are more than double the rate in the least
deprived areas (56) and this is partly explained by inequalities
in existing chronic health conditions. Furthermore, people
from ethnic minority backgrounds are overrepresented among
deaths from COVID-19 (57–59), with ethnicity apparently a
risk factor independent of deprivation (60), probably partly
due to higher prevalence of common comorbidities. In
addition, there are numerous social and structural factors
that increase risk of infection in these groups (such as
overcrowded housing, greater reliance on public transport,
and employment in essential and “frontline” occupations
with much human contact where physical distancing is
not feasible).
People with chronic health conditions are already
disadvantaged and underrepresented in the workforce. They
have been further disadvantaged by control measures such as
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prolonged shielding – which can adversely affect their financial,
social, and mental well-being. Further use of such measures –
in this or another pandemic - will require tailored support and
strategies to mitigate impacts.
Without concerted effort, reducing existing risk
factors such as obesity and targeting support for people
with pre-existing health conditions, the COVID-19
pandemic is likely to widen health inequalities between
social, ethnic, and geographical groups. Pandemic
responses must therefore prioritise and mitigate the
unfair burden shouldered by disadvantaged and ethnic
minority groups.
CONCLUSIONS
Building on evidence that people with comorbidities were
overrepresented in hospitalised cases of COVID-19, this review
compiled estimates from age-adjusted regression models across
14 studies from various settings globally in the early stages
of the pandemic. It summarises for clinicians, policymakers,
and academics the most robust evidence that was available
in those first few months on this topic, to inform decision-
making. Characterising this early evidence base helps to
provide crucial context for the many enquiries, probes, and
reflective exercises that will be performed around the world
to scrutinise what should have been done better in the early
response. Despite its limitations, the early evidence base showed
that people with underlying chronic health conditions are at
increased risk of severe disease progression and death and
supported a range of public health and clinical approaches to
protecting people with comorbidities. Given the distribution of
comorbidities in the community, this evidence indicates that
COVID-19 will exacerbate existing health inequalities, unless
actions are taken to reduce these pre-existing vulnerabilities
and target control measures to protect groups with chronic
health conditions.
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